Clinical Trials Logo

Renal Denervation clinical trials

View clinical trials related to Renal Denervation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04321044 Active, not recruiting - Hypertension Clinical Trials

Genetic Based Analysis in Hypertensive Patients

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Many attempts to identify predictors of blood pressure response after renal denervation failed to identify a meaningful determination of blood pressure response. These attempts have been based on demographic parameters, clinical parameters, endocrine inflammatory and other biochemical variables, comorbidities and disease factors. So far the only predictor of blood pressure response is the pre-treatment blood pressure. According to Wilder's law the pre-treatment baseline value is always a determinant for any change due to an intervention, irrespective which biological variable is examined. The investigators propose a genetic approach to identify predictors of blood pressure response after renal denervation. Genetic factors are not subject to changes of clinical parameters, previous or current antihypertensive therapy, hypertension associated organ damages, comorbidities and other potential clinical variables.

NCT ID: NCT04264403 Active, not recruiting - Clinical trials for Uncontrolled Hypertension

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study

RDN-CKD
Start date: January 23, 2020
Phase: N/A
Study type: Interventional

RDN-CKD Study is a prospective, randomized (1:1, central randomization), double-blind (unblinded interventionalist and blinded study team at each center), sham controlled, multicenter feasibility study. The purpose of the RDN-CKD Study is to demonstrate that renal denervation (RDN) effectively reduces 24-h ambulatory BP in 80 patients with chronic kidney disease (CKD) stage 3a or 3b.